Safety and Efficacy Study of Autologous Cultured Adipose -Derived Stem Cells for the Crohn's Fistula
Status:
Completed
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
Up to date, a sure cure for Crohn's fistula has not known and the fistula recurrence rate is
high. On 15 October 2008, orphan drug designation was granted by Korea FDA to Anterogen Co.
Ltd., for human adipose-derived stem cell. In this study, patients are given injection of
ADIPOPLUS in fistula site and followed for 8 weeks to test the safety and efficacy.